# Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis

> **NCT04453137** · PHASE3 · COMPLETED · sponsor: **Alvotech Swiss AG** · enrollment: 567 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **BIOLOGICAL:** Adalimumab originator
- **BIOLOGICAL:** Adalimumab biosimilar

## Key facts

- **NCT ID:** NCT04453137
- **Lead sponsor:** Alvotech Swiss AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-30
- **Primary completion:** 2021-05-31
- **Final completion:** 2021-11-16
- **Target enrollment:** 567 (ACTUAL)
- **Last updated:** 2022-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04453137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04453137, "Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04453137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*